Result: 41 - 60 of 96
DRAMP IDNAMEDescriptionMedical_useStage of developmentCompany
DRAMP18152IMX942(Inimex)Synthetic cationic host defense peptide,derivative of IDR-1 and indolicidinTreatment for chemotherapeutic induced neutropenia, nosocomial infectionsPhase IIInimex
DRAMP18153Opebacan21-amino-acid peptide derivative of bactericidal/permeability-increasing proteinEndotoxemia in hematopoetic, stem cell transplant, recipientsPhase I/IIXoma
DRAMP18154XOMA-6299-amino-acid peptide derivative of bactericidal/permeability-increasing proteinImpetigoPhase IIIXoma
DRAMP18155DiaPep277DiaPep277 is a small, lyophilized powder containing 24 Amino-acids. It has proved in former studies that DiaPep277 can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.Type 1 diabetes mellitusPhase IIIDeveloGen
DRAMP18156RDP58(Delmitide)Semisynthetic D-amino acid decapeptide derived from HLA class I B2702Inflammatory bowel diseasePost Phase IIGenzyme; licensed to Procter&Gamble
DRAMP18157NVXT (Novexatin, NP213)cyclic cationic peptide derived from NovaBiotics arginine peptide platformOnychomycosis (fungal nail infection)Phase IIbNovaBiotics
DRAMP18158PMX-30063(brilacidin)Defensin structural mimetic, non-peptide,small molecule/copolymerAcute bacterial skin infections caused by StaphylococcussppPhase IIPolyMedix
DRAMP18159OritavancinOritavancin is a glycopeptide antibiotic used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria. It was developed by The Medicines Company (acquired by Novartis).Treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection.In marketThe Medicines Company
DRAMP18161OP-145 (AMP60.4Ac)Synthetic 24-mer peptide derived from LL-37 for binding to lipopolysaccharides or lipoteichoic acidChronic suppurative otitis media (middle ear infections)Phase II (Completed)OctoPlus BV, Dr Reddy’s Research and Development BV
DRAMP18162BL2060Synthetic compound comprising fatty acid and lysine copolymersAnti-infectiveLead optimizationBioLineRx (Jerusalem).
DRAMP18163GhrelinEndogenous host-defence peptide,Synthetic constructAirway inflammation, chronic respiratory infection and cystic fibrosis, cnacerPhase II (Completed)University of Miyazaki Third Department of Internal Medicine (Japan) and Papworth Hospital (UK).
DRAMP18164AP-214(Modimelanotide)Synthetic derivative from HDP α-melanocyte-stimulating hormone①Prevention of acute kidney injury after cardiac surgery; ②Treatment of sepsis.Phase II (Completed)Action Pharma A/S (Aarhus and Copenhagen, Denmark)
DRAMP18165CD-NP(Cenderitide)Synthetic chimeric 37-mer derived from combination of two natriuretic peptidesAcute decompensated failure (ADHF),Organ failurePhase IINile Therapeutics (United States, Minnesota).
DRAMP18166Vasoactive intestinal peptide (VIP; Endogenous HDP)No more descriptionAcute Respiratory Distress Syndrome and SepsisPhase IStony Brook University and State University of New York (United States, New York).
DRAMP18167Ruminococcin C (Bacteriocin)Ruminococcus gnavus E1Gastrointestinal tract infections; Stomach and intestine infections (Rat model; In-vivo)PreclinicalUnknown
DRAMP18168Planosporicin (Bacteriocin)Planomonospora sp. DSM14920Hospital-acquired infections; Multi-drug resistant strain (Murine model; In-vivo)PreclinicalUnknown
DRAMP18169ESL5Enterococcus faecalis SL-5Gastrointestinal tract infections; Stomach and intestine infections (Human model; In-vivo)PreclinicalUnknown
DRAMP18170Colicin E1 (Bacteriocin)Escherichia coli H22Gastrointestinal tract infections; Stomach and intestine infections (Murine model; In-vivo) PreclinicalUnknown
DRAMP18171Lactocin 160 (Bacteriocin)Lactobacillus rhamnosus 160Urogenital tract infections; Bacterial vaginosisPreclinicalUnknown
DRAMP18172Bacteriocin OR-7Lactobacillus salivarius NRRL B-30514Gastrointestinal tract infections; Campylobacter infection (Chicken model; In-vivo)PreclinicalUnknown
Sign in     login

Forgot your password?